Gilead's Biktarvy Approval Heightens HIV Competition With ViiV

Gilead hopes Biktarvy will enable it to win market share away from ViiV's dolutegravir-containing regimens, but ViiV filed a patent infringement case within hours of the US FDA approval of Gilead's new combo.

HIV-AIDS pills_1200x675

Gilead Sciences Inc. has been waiting for its new daily fixed-dose combination therapy for HIV, now known as Biktarvy, to provide new ammunition in its battle for HIV market share against ViiV Healthcare. But the competition wasted no time striking back with a patent infringement suit.

The US FDA's Feb. 7 approval of Biktarvy (BIC/F/TAF) – consisting of the novel integrase inhibitor bictegravir, the second-generation nucleotide...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip